Therefore, the renoprotective effect of SYFSF is at least partially attributed to breaking the vicious circle between inflammatory response and dyslipidemia by inhibiting the TNF-α/NF-κB pathway. The gene discussed is NFKB1; the disease is metabolic syndrome.